A British biotech based in Cambridge, England, raised $86 million to advance an antibody drug designed to deplete protein deposits in people with amyloidosis.
The company, called Immutrin, was co-founded by Gregory Winter. He won …
A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.
The pill version of Novo Nordisk’s blockbuster Wegovy showed what was possible when drug chemists turned peptides into oral molecules. Now investors have found their
Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.
Denali’s Avlayah is the first drug for neurological complications associated Hunter syndrome to be approved in the US.
The FDA granted accelerated approval to Denali Therapeutics’ rare disease drug Avlayah, bucking a recent trend of rejections in the space that has put the
A British biotech based in Cambridge, England, raised $86 million to advance an antibody drug designed to deplete protein deposits in people with amyloidosis.
The company, called Immutrin, was co-founded by Gregory Winter. He won …